ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026
Irritable Bowel Syndrome Clinical Care Gaps and the Potential of Future Therapeutics Based on Peripheral Visceral Afferent Modulation.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cannabigerol at the Interface of the Gut Microbiota and EndoCannabinoidome: Mechanistic Insights into Inflammation and Pain Modulation.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Current management of irritable bowel syndrome (IBS) is focused on bowel dysfunction or central neuromodulators. The aims of this review were to: appraise unmet needs in IBS treatment; review the physiology of visceral afferent functions and specifically receptors in the dorsal root ganglion (DRG) cell bodies of the first order neurones; and summarize evidence of efficacy of pharmacological approaches directed at receptors expressed by DRGs based on rodent models of visceral hypersensitivity and randomized controlled trials in IBS. A literature search was done using terms identified in the aims section. The greatest need in IBS is safe treatment of pain. Physiological and noxious stimuli are conducted to the brain through vagal and pelvic parasympathetic pathways, and noxious stimuli through visceral afferents and spinal cord. Peripheral visceral afferents, with cell bodies in DRG, have receptors targeted pharmacologically to relieve pain (or surrogates) in rodent IBS models of visceral hypersensitivity. Advances in understanding mechanisms of visceral hypersensitivity lead to consideration of targeting receptors on the DRG. Those receptors on DRGs are also expressed in the central nervous system and include α-2 adrenergic, somatostatin-SS2, 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.